Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab + TGR-1202 with or without bendamustine versus TGR-1202 alone in previously treated non-Hodgkin lymphoma
2016-004718-90Phase 2Unknown
- Sponsor
- TG Therapeutics, Inc.
- Start
- Dec 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more comparing TGR-1202 alone, TGR-1202 + ublituximab and TGR-1202 + ublituximab + bendamustine (3 arms). Primary endpoint: Overall response rate. Status: unknown.
02
Drugs
ublituximabumbralisibbendamustine
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2016-004718-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004718-90.